Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy
PLOS Biology · 17.03.2026 · 24 (3) · e3003657
DOI: 10.1371/journal.pbio.3003657 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, online erschienen am 17.03.2026. Verfasst von Chenghao Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Helmholtz International Lab for Anti-Infectives, Shandong University…. Hauptthemen laut MEDLINE: Depsipeptides, Escherichia coli, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds of Shandong University, Future Plan for Young Sholars of Shandong University.
Abstract (Originalsprache)
The probiotic strain Escherichia coli Nissle 1917 (EcN), a potential member of tumor-targeting bacteria, shows great promise for cancer treatment. By leveraging engineered EcN, we can design a bacteria-assisted, tumor-targeted therapy for the biosynthesis and targeted delivery of small-molecule anticancer agents. In this study, we aimed to use EcN as a base for synthesizing Romidepsin (FK228), an FDA-approved drug originally made by Chromobacterium violaceum No. 96. Through gene cluster reconstruction, promoter optimization, and genome modification, we created FK228-producing strains to boost anticancer efficacy. The engineered strain achieved a maximum in vitro yield of 1.5 mg/L. In 4T1 tumor-bearing BALB/c mouse xenograft models, six recombinant strains outperformed the wild-type EcN. Proteome showed that inflammatory response induced by EcN combined with intratumoral FK228 production improved treatment results. Also, targeted synthesis reduced FK228's cardiotoxicity and mortality. Engineered EcN enables drug biosynthesis and precise delivery, offering powerful anticancer activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Helmholtz International Lab for Anti-Infectives, Shandong University-Helmholtz Institute of Biotechnology, Shandong University, Qingdao, C…
- School of Life Sciences, Shandong University, Qingdao, China.
- Shenzhen Key Laboratory of Genome Manipulation and Biosynthesis, Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of…
ORCID-Profile: Tianyu Jiang
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds of Shandong University
- Future Plan for Young Sholars of Shandong University
- Fund for Distinguished Young Scholars of SDU
- Natural Science Foundation of Shandong Province
- SKLMT Frontiers and Challenges Project
- Shenzhen Science and Technology Program
- 111 Project
Zitieren
APA
Ma, C., Li, G., Sun, T., Tang, X., Qiu, T., Song, J., Wang, H., Zhang, Y., & Jiang, T. (2026). Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy. PLOS Biology, 24(3), e3003657. https://doi.org/10.1371/journal.pbio.3003657
Vancouver
Ma C, Li G, Sun T, Tang X, Qiu T, Song J, et al. Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy. PLOS Biology. 2026;24(3):e3003657. doi:10.1371/journal.pbio.3003657
BibTeX
@article{Ma2026,
author = {Ma, Chenghao and Li, Geng and Sun, Tao and Tang, Ximi and Qiu, Tong and Song, Jingwen and Wang, Hailong and Zhang, Youming and Jiang, Tianyu},
title = {Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy},
journal = {PLOS Biology},
year = {2026},
volume = {24},
number = {3},
pages = {e3003657},
doi = {10.1371/journal.pbio.3003657}
}
EUVIMED